| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
BRIEF COMMUNICATION |
Departments of Physiology & Biophysics (M.L.G., M.J.C., J.T.S., S.M.P., R.A.S.), Obstetrics & Gynecology (B.V.A., D.K.C., R.A.S.), and Biology (R.A.S.), University of Washington, Seattle, Washington 98195-7290; and the Massachusetts General Hospital (W.F.C., S.S.), Harvard Medical School, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Robert A. Steiner, Department of Physiology & Biophysics Health Sciences Building, G-424 School of Medicine University of Washington, Box 357290, 1959 Northeast Pacific Street, Seattle, Washington 98195-7290. E-mail: steiner{at}u.washington.edu.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Signaling through GPR54 is essential for pubertal maturation of the reproductive system. Humans and mice having either dysfunctional or deletional mutations in GPR54 fail to undergo normal pubertal development as a result of hypogonadotropic hypogonadism (6, 7, 8). Although the precise anatomical distribution of KiSS-1 and GPR54 are not well characterized, both are expressed in the mammalian forebrain (1, 9), and thus, we postulated that kisspeptin/GPR54 signaling in the hypothalamus may be involved in the neuroendocrine regulation of gonadotropin secretion. We had three specific objectives. The first was to examine the effects of centrally administered kisspeptin-54 (metastin) and kisspeptin-10 on LH secretion and to create a full dose-response curve for kisspeptin-54. Second, having observed that kisspeptin-54 stimulated gonadotropin secretion, we tested the hypothesis that the kisspeptin-54-induced gonadotropin response (LH and FSH) was mediated by GnRH. We accomplished this by examining whether pretreatment with acyline, a potent GnRH antagonist, could block the kisspeptin-54-induced release of LH and FSH. The third objective was to map the detailed distribution of KiSS-1 mRNA within the hypothalamus of the mouse, searching for its presence in areas known to be involved in the regulation of GnRH secretion.
| Materials and Methods |
|---|
|
|
|---|
Kisspeptin-54 [KiSS-1 (68119)-NH2 (mouse)/metastin (152)] was purchased from Phoenix Pharmaceutical (Belmont, CA). Kisspeptin-10 [KiSS-1 (112121)/ metastin (4554) (human)] was provided by the Peptide Core Facility of the Massachusetts General Hospital (Boston, MA). Acyline, a GnRH antagonist (10, 11, 12), was a gift from Dr. William J. Bremner (University of Washington, Seattle, WA). Acyline was synthesized by Jean Rivier at The Salk Institute (La Jolla, CA) and distributed by the National Institute of Child Health and Human Development (10).
Intracerebroventricular (ICV) injections
Freehand ICV injections in the lateral cerebral ventricle were performed as previously described (13, 14). Briefly, mice were anesthetized with isoflurane (Abbott Laboratory, North Chicago, IL) delivered by a vaporizer (Veterinary Anesthesia Systems, Bend, OR). Upon achieving a surgical plane of anesthesia, a small hole was bored in the skull 1 mm lateral and 0.5 mm posterior to bregma with a Hamilton syringe attached to a 27-gauge needle fitted with polyethylene tubing, leaving 3.5 mm of the needle tip exposed. Once the initial hole was made, all subsequent injections were made at the same site. Mice were allowed to recover for at least 2 d before treatment. For ICV injections, mice were anesthetized with isoflurane for a total of 23 min, during which time 3 µl of solution were slowly and continuously injected into the lateral ventricle. The needle remained inserted for approximately 60 sec after the injection to minimize backflow up the needle track. Mice typically recovered from the anesthesia within 3 min after the injection.
RIAs
Serum LH and FSH concentrations were measured with reagents obtained from the National Institutes of Health. For LH, the antiserum used was anti-rLH-S-11, and the standard was rLH-RP3. The assay sensitivity was 0.2 ng/ml, and the intraassay coefficient of variation was 7%. For FSH, the antiserum used was anti-rFSH-S-11, and the standard was rFSH-RP2. The assay sensitivity was 1.0 ng/ml, and the intraassay coefficient of variation was 6%. Both assays have been validated for use in the mouse.
Experiment 1: LH response to ICV kisspeptin-54 and kisspeptin-10
Mice were handled daily for 2 wk before the experiment. Mice were given an ICV injection of one of four treatments: kisspeptin-54 (1 nmol) dissolved in artificial cerebrospinal fluid (aCSF), kisspeptin-10 (1 nmol) dissolved aCSF + 15% dimethylsulfoxide (DMSO), aCSF + 15% DMSO alone, or aCSF alone (n = 5 per group). Blood was obtained via orbital bleed 30 min post injection while mice were under isoflurane anesthesia, and sera were assayed for LH. We measured the LH response to both kisspeptin-54 and kisspeptin-10 to confirm the putative biological activity of both ligands in the context of gonadotropin secretion. The 30-min time interval between the injection and the blood sampling was selected based on the observation that other secretagogs that stimulate LH secretion in a GnRH-dependent fashion do so within this time frame (14, 15).
Experiment 2: LH response to variable doses of central kisspeptin-54
Mice were given an ICV injection of kisspeptin-54 in doses varying from 1 fmol to 5 nmol or aCSF alone (n = 58 per group). Doses administered include 1 fmol, 10 fmol, 0.1 pmol, 1 pmol, 10 pmol, 0.1 nmol, 0.375 nmol, 0.625 nmol, 1.25 nmol, 2.5 nmol, and 5 nmol. Blood was obtained via orbital bleed 30 min post injection while mice were under isoflurane anesthesia, and sera were assayed for LH.
Experiment 3: role of GnRH in mediating the effects of kisspeptin-54 on LH and FSH secretion
Mice received an sc injection of acyline (50 µg) dissolved in sterile saline (100 µl/mouse) 24 h and 1 h before ICV injection of kisspeptin-54 or aCSF alone. Control mice were given an sc injection of saline only at 24 h and 1 h before ICV injections. On the day of the experiment, mice received either an ICV injection of kisspeptin-54 (0.05 nmol) or aCSF alone. Of the mice that had been given acyline, half were treated with kisspeptin-54 and the other half received aCSF (n = 6/group). Similarly, half of the mice that had been treated with saline were given kisspeptin-54, and the other half received aCSF (n = 6/group). Blood was obtained by orbital bleed 60 min post ICV injection, while mice were under isoflurane anesthesia and sera were assayed for LH and FSH. Mice were not used in a crossover design.
Measurement of gonadotropins in the acyline treatment experiment was done at 60 min after the injection, upon reflection of the results from the first experiment, which had revealed that kisspeptin-54 caused a slight but not significant increase in serum levels of FSH (data not shown). Because the FSH response to secretagogs for gonadotropins is often delayed relative to LH, we decided to increase the interval between the injection and the blood sample by another 30 min to optimize the chance of revealing an FSH response to kisspeptin-54.
Experiment 4: distribution of KiSS-1 mRNA in the hypothalamus of the mouse
Tissue preparation.
Mice were anesthetized with isoflurane and then killed by decapitation. Brains were removed and frozen on dry ice. Sections in the coronal plane (20 µm) were cut on a cryostat, thaw-mounted onto SuperFrost Plus slides (VWR Scientific, West Chester, PA), and stored at 80 C. Sections were collected from the diagonal band of Broca to the mammillary bodies.
Cloning of partial cDNA for mouse KiSS-1.
Total RNA was extracted from mouse brain using an RNAqueous Kit (Ambion, Inc., Austin, TX). RNA was reverse transcribed into cDNA with a RetroScript kit (Ambion) primed with oligodeoxythymidine for subsequent PCR. Primers were designed based on the published sequence of the KiSS-1 mouse gene (GenBank accession no. AF472576) with forward primers corresponding to bases 7693 and reverse primers corresponding to bases 466486. Primers were custom synthesized (QIAGEN, Valencia, CA). PCRs contained the following in a volume of 25 µl: 2 µl of reverse transcriptase reaction product; 0.2 µM of each primer; 12.5 µl RediTaq polymerase (Sigma-Aldrich, Natick, MA); and 8.5 µl of water. Reactions were performed in a PTC-100 thermal cycler (MJ Research, Inc., Watertown, MA) using the following protocol: cDNA was denatured for 2 min at 94 C, then 35 cycles were carried out at 94 C for 1 min, 55 C for 1.5 min, and 72 C for 2 min, with a final 5 min extension at 72 C. After electrophoresis on a 2% agarose (wt/vol) gel, a single DNA fragment was obtained of approximately the expected size (411 bp) and gel purified with a QiaQuick gel extraction kit (QIAGEN). The PCR product was confirmed to be the mouse KiSS-1 probe by sequencing and was cloned into the pAMP1 plasmid (Invitrogen Life Technologies, Carlsbad, CA).
In situ hybridization.
Antisense and sense mouse KiSS-1 probes were transcribed from linearized pAMP1 plasmid containing the mouse KiSS-1 insert with T7 and SP6 Polymerase Plus (Ambion), respectively. Radiolabeled probes were synthesized in vitro by inclusion of the following ingredients in a volume of 20 µl: 250 µCi 33P-UTP (PerkinElmer Life Sciences, Boston, MA); 1 µg linearized DNA; 0.5 mM each ATP, CTP, GTP; 40 U polymerase. Residual DNA was digested with 4 U deoxyribonuclease (Ambion), and the deoxyribonuclease reaction was terminated by addition of 2 µl of 0.5 M EDTA (pH 8.0). The riboprobes were separated from unincorporated nucleotides with NucAway Spin Columns (Ambion).
Slides with mouse hypothalamic sections from three adult male C57BL/6 mice were processed before hybridization as previously reported (16). Radiolabeled antisense and sense KiSS-1 riboprobes were denatured, dissolved in hybridization solution at a concentration of 0.1 pmol/ml along with tRNA (1.9 mg/ml), and applied to slides. Two negative controls were used to demonstrate specificity of the KiSS-1 riboprobe: slides were incubated with radiolabeled antisense probe in the presence of excess (500x) unlabeled antisense probe, or with an equivalent concentration of radiolabeled sense KiSS-1 probe. Slides were covered with glass coverslips, placed in a humid chamber, and incubated overnight at 55 C. The next day, slides were washed as previously reported (16). Slides were then dipped in NTB-3 liquid emulsion (Eastman Kodak Co., Rochester, NY). Slides were developed 3 d later, and coverslips were applied.
Statistical analysis
All data are expressed as a mean ± SEM for each group. Differences among groups were assessed by one- or two-way ANOVA. When the ANOVA indicated significant differences, Fishers post hoc test was used to identify differences between individual treatment groups. Students t test was used when only two groups were being compared. Differences were considered significant when P < 0.05.
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Our results also demonstrate that the ability of kisspeptin-54 to stimulate gonadotropin release is dependent upon GnRH secretionbased on the observations that pretreatment with a GnRH antagonist blocks the effect of kisspeptin-54. These results are consistent with the phenotype of GPR54-deficient mice whose pituitaries are capable of secreting LH in response to exogenous GnRH, despite their gonadotropin deficiency. Together, these observations argue that the hypogonadism in humans and mice with dysfunctional or deletional mutations in GPR54 is attributable to a central defect (7). Based on these findings, we infer that kisspeptin-54 activates its cognate receptor GPR54 to provide an obligatory activational signal to GnRH neurons at the time of puberty. However, precisely where in the brain kisspeptin-54 acts to stimulate GnRH secretion is unknown. Although GPR54 mRNA is expressed throughout the forebrain (1, 9)notably in areas of the brain where GnRH neurons are known to reside (20)it remains to be determined whether GnRH neurons themselves express GPR54 or the action of kisspeptin-54 on GnRH secretion is mediated indirectly by intervening neurons.
Despite the inference that kisspeptin-54 stimulates GnRH secretion, we cannot exclude the possibility that the centrally administered kisspeptin-54 gained access to the pituitary and thus directly stimulated LH and FSH release from the pituitary. This is at least conceivable because GPR54 is expressed in the pituitary (2, 9). However, we believe this explanation is improbable for two reasons. First, kisspeptin-54 is unusually potent at stimulating LH release, retaining its effectiveness at doses as low as 1 fmol. The efficacy of such low doses of kisspeptin-54 delivered into the brain to stimulate LH secretion would mitigate the probability that kisspeptin-54, diffusing and diluting from its site of delivery in the lateral ventricle could retain sufficient activity to stimulate pituitary gonadotropes. Second, the ability of kisspeptin-54 to stimulate LH secretion by a direct action on the pituitary should not have been impaired by the presence of the GnRH antagonist acyline. Nevertheless, it is still plausible that kisspeptin-54 could be acting synergistically with GnRH, similar to neuropeptide Y to affect LH release (21); this possibility cannot be excluded.
The distribution of KiSS-1 mRNA has been examined grossly in the brain of both the rat and human by RT-PCR, and transcripts for this gene are detectable (1, 9); however, the precise regional distribution of KiSS-1 mRNA within the forebrain has not been carefully annotated for any species. In this study in the mouse, we observed KiSS-1 mRNA-expressing cells in discrete hypothalamic nuclei, including the AVPV, PeN, and ARC. Muir and colleagues (9) also report finding significant expression of KiSS-1 in several other areas in the brain of the humansuch as the caudate nucleus, globus pallidus, nucleus accumbens, putamen, and striatum; however, in the mouse, we did not find KiSS-1 mRNA in any of these extrahypothalamic regions. Whether these apparent differences between the human and mouse represent real species differences or a disparity of the sensitivity in the respective techniques remains to be determined.
Based on the distribution of KiSS-1 mRNA, we surmise that kisspeptin-54 may be involved in the hypothalamic regulation of GnRH/gonadotropin secretion by gonadal steroids. Receptors for androgens, estrogens, and progesterone are expressed in the hypothalamic nuclei that express KiSS-1 mRNA, including the ARC and AVPV (22, 23, 24). These nuclei are both implicated in the negative feedback control of gonadotropin secretion in both sexes (25), and the AVPV is specifically implicated in mediating the positive feedback effects of estrogen on GnRH during the preovulatory LH surge (26, 27). Terminals projecting from cell bodies in the AVPV are found in close apposition to GnRH-containing perikarya (28); however, whether these terminals are derived from kisspeptin-54-expressing neurons whose cell bodies reside in the AVPV (or ARC) remains to be elucidated. Moreover, it will be of considerable interest to determine whether sex steroids regulate the KiSS-1 gene.
In summary, we have shown that KiSS-1 mRNA is expressed in regions of the hypothalamus known to be involved in the regulation of gonadotropin secretion, and products of the KiSS-1 gene have a potent stimulatory effect on GnRH secretion. We conclude that kisspeptins and their receptor are part of the hypothalamic circuitry that governs the neuroendocrine reproductive axis.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: aCSF, Artificial cerebrospinal fluid; ARC, arcuate nucleus; AVPV, anteroventral periventricular nucleus; DMSO, dimethylsulfoxide; GPR54, a novel G protein-coupled receptor; ICV, intracerebroventricular; PeN, periventricular nucleus.
Received April 5, 2004.
Accepted for publication June 15, 2004.
| References |
|---|
|
|
|---|
B binding to the promoter as a consequence of I
B
-induced block of p65/p50 nuclear translocation. J Biol Chem 276:11641172
and -ß mRNA in the rat central nervous system. J Comp Neurol 388:507525[CrossRef][Medline]
This article has been cited by other articles:
![]() |
X. d'Anglemont de Tassigny, L. A. Fagg, M. B. L. Carlton, and W. H. Colledge Kisspeptin Can Stimulate Gonadotropin-Releasing Hormone (GnRH) Release by a Direct Action at GnRH Nerve Terminals Endocrinology, August 1, 2008; 149(8): 3926 - 3932. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Keen, F. H. Wegner, S. R. Bloom, M. A. Ghatei, and E. Terasawa An Increase in Kisspeptin-54 Release Occurs with the Pubertal Increase in Luteinizing Hormone-Releasing Hormone-1 Release in the Stalk-Median Eminence of Female Rhesus Monkeys in Vivo Endocrinology, August 1, 2008; 149(8): 4151 - 4157. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A Lents, N. L Heidorn, C R. Barb, and J J. Ford Central and peripheral administration of kisspeptin activates gonadotropin but not somatotropin secretion in prepubertal gilts Reproduction, June 1, 2008; 135(6): 879 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Roa, E. Vigo, D. Garcia-Galiano, J. M. Castellano, V. M. Navarro, R. Pineda, C. Dieguez, E. Aguilar, L. Pinilla, and M. Tena-Sempere Desensitization of gonadotropin responses to kisspeptin in the female rat: analyses of LH and FSH secretion at different developmental and metabolic states Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1088 - E1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gonzalez-Martinez, C. De Mees, Q. Douhard, C. Szpirer, and J. Bakker Absence of Gonadotropin-Releasing Hormone 1 and Kiss1 Activation in {alpha}-Fetoprotein Knockout Mice: Prenatal Estrogens Defeminize the Potential to Show Preovulatory Luteinizing Hormone Surges Endocrinology, May 1, 2008; 149(5): 2333 - 2340. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kanda, Y. Akazome, T. Matsunaga, N. Yamamoto, S. Yamada, H. Tsukamura, K.-i. Maeda, and Y. Oka Identification of KiSS-1 Product Kisspeptin and Steroid-Sensitive Sexually Dimorphic Kisspeptin Neurons in Medaka (Oryzias latipes) Endocrinology, May 1, 2008; 149(5): 2467 - 2476. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Hill, J. K. Elmquist, and C. F. Elias Hypothalamic pathways linking energy balance and reproduction Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E827 - E832. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zhang, T. A. Roepke, M. J. Kelly, and O. K. Ronnekleiv Kisspeptin Depolarizes Gonadotropin-Releasing Hormone Neurons through Activation of TRPC-Like Cationic Channels J. Neurosci., April 23, 2008; 28(17): 4423 - 4434. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pielecka-Fortuna, Z. Chu, and S. M. Moenter Kisspeptin Acts Directly and Indirectly to Increase Gonadotropin-Releasing Hormone Neuron Activity and Its Effects Are Modulated by Estradiol Endocrinology, April 1, 2008; 149(4): 1979 - 1986. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Smith, A. Rao, A. Pereira, A. Caraty, R. P. Millar, and I. J. Clarke Kisspeptin Is Present in Ovine Hypophysial Portal Blood But Does Not Increase during the Preovulatory Luteinizing Hormone Surge: Evidence that Gonadotropes Are Not Direct Targets of Kisspeptin in Vivo Endocrinology, April 1, 2008; 149(4): 1951 - 1959. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Revel, M. Saboureau, P. Pevet, V. Simonneaux, and J. D. Mikkelsen RFamide-Related Peptide Gene Is a Melatonin-Driven Photoperiodic Gene Endocrinology, March 1, 2008; 149(3): 902 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Kinsey-Jones, X. F. Li, S. M. Luckman, and K. T. O'Byrne Effects of Kisspeptin-10 on the Electrophysiological Manifestation of Gonadotropin-Releasing Hormone Pulse Generator Activity in the Female Rat Endocrinology, March 1, 2008; 149(3): 1004 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Phillips and R. D. Palmiter Role of Agouti-Related Protein-Expressing Neurons in Lactation Endocrinology, February 1, 2008; 149(2): 544 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Goodman, M. N. Lehman, J. T. Smith, L. M. Coolen, C. V. R. de Oliveira, M. R. Jafarzadehshirazi, A. Pereira, J. Iqbal, A. Caraty, P. Ciofi, et al. Kisspeptin Neurons in the Arcuate Nucleus of the Ewe Express Both Dynorphin A and Neurokinin B Endocrinology, December 1, 2007; 148(12): 5752 - 5760. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Caraty, J. T. Smith, D. Lomet, S. Ben Said, A. Morrissey, J. Cognie, B. Doughton, G. Baril, C. Briant, and I. J. Clarke Kisspeptin Synchronizes Preovulatory Surges in Cyclical Ewes and Causes Ovulation in Seasonally Acyclic Ewes Endocrinology, November 1, 2007; 148(11): 5258 - 5267. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Dungan, M. L. Gottsch, H. Zeng, A. Gragerov, J. E. Bergmann, D. K. Vassilatis, D. K. Clifton, and R. A. Steiner The Role of Kisspeptin GPR54 Signaling in the Tonic Regulation and Surge Release of Gonadotropin-Releasing Hormone/Luteinizing Hormone J. Neurosci., October 31, 2007; 27(44): 12088 - 12095. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Dhillo, O. B. Chaudhri, E. L. Thompson, K. G. Murphy, M. Patterson, R. Ramachandran, G. K. Nijher, V. Amber, A. Kokkinos, M. Donaldson, et al. Kisspeptin-54 Stimulates Gonadotropin Release Most Potently during the Preovulatory Phase of the Menstrual Cycle in Women J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3958 - 3966. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, D. Mitchell, J. Luo, Z. Yi, S.-G. Cho, J. Guo, X. Li, G. Ning, X. Wu, and M. Liu Estrogen Regulates KiSS1 Gene Expression through Estrogen Receptor {alpha} and SP Protein Complexes Endocrinology, October 1, 2007; 148(10): 4821 - 4828. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J Todd, G. S Fraley, A. C Peck, G. J Schwartz, and A. M Etgen Central Insulin-Like Growth Factor 1 Receptors Play Distinct Roles in the Control of Reproduction, Food Intake, and Body Weight in Female Rats Biol Reprod, September 1, 2007; 77(3): 492 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Kauffman, J. H. Park, A. A. McPhie-Lalmansingh, M. L. Gottsch, C. Bodo, J. G. Hohmann, M. N. Pavlova, A. D. Rohde, D. K. Clifton, R. A. Steiner, et al. The Kisspeptin Receptor GPR54 Is Required for Sexual Differentiation of the Brain and Behavior J. Neurosci., August 15, 2007; 27(33): 8826 - 8835. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. d'Anglemont de Tassigny, L. A. Fagg, J. P. C. Dixon, K. Day, H. G. Leitch, A. G. Hendrick, D. Zahn, I. Franceschini, A. Caraty, M. B. L. Carlton, et al. Hypogonadotropic hypogonadism in mice lacking a functional Kiss1 gene PNAS, June 19, 2007; 104(25): 10714 - 10719. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamada, Y. Uenoyama, M. Kinoshita, K. Iwata, K. Takase, H. Matsui, S. Adachi, K. Inoue, K.-I. Maeda, and H. Tsukamura Inhibition of Metastin (Kisspeptin-54)-GPR54 Signaling in the Arcuate Nucleus-Median Eminence Region during Lactation in Rats Endocrinology, May 1, 2007; 148(5): 2226 - 2232. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Kauffman, M. L. Gottsch, J. Roa, A. C. Byquist, A. Crown, D. K. Clifton, G. E. Hoffman, R. A. Steiner, and M. Tena-Sempere Sexual Differentiation of Kiss1 Gene Expression in the Brain of the Rat Endocrinology, April 1, 2007; 148(4): 1774 - 1783. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tenenbaum-Rakover, M. Commenges-Ducos, A. Iovane, C. Aumas, O. Admoni, and N. de Roux Neuroendocrine Phenotype Analysis in Five Patients with Isolated Hypogonadotropic Hypogonadism due to a L102P Inactivating Mutation of GPR54 J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1137 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Greives, A. O. Mason, M.-A. L. Scotti, J. Levine, E. D. Ketterson, L. J. Kriegsfeld, and G. E. Demas Environmental Control of Kisspeptin: Implications for Seasonal Reproduction Endocrinology, March 1, 2007; 148(3): 1158 - 1166. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Smith, C. M. Clay, A. Caraty, and I. J. Clarke KiSS-1 Messenger Ribonucleic Acid Expression in the Hypothalamus of the Ewe Is Regulated by Sex Steroids and Season Endocrinology, March 1, 2007; 148(3): 1150 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lee, J. K. Hiney, M. D. Pine, V. K. Srivastava, and W. L. Dees Manganese stimulates luteinizing hormone releasing hormone secretion in prepubertal female rats: hypothalamic site and mechanism of action J. Physiol., February 1, 2007; 578(3): 765 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Mead, J. J. Maguire, R. E. Kuc, and A. P. Davenport Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels Endocrinology, January 1, 2007; 148(1): 140 - 147. |